M. Nagamani et R. Urban, Increased expression of messenger ribonucleic acid encoding cytochrome P450 cholesterol side-chain cleavage and P450 17 alpha-hydroxylase enzymes in ovarian hyperthecosis, FERT STERIL, 71(2), 1999, pp. 328-333
Objective: To investigate whether the increased ovarian androgen synthesis
in hyperthecosis is due to increased expression of the steroidogenic enzyme
s essential for androgen synthesis.
Design: Controlled study to investigate concentration of steroidogenic enzy
mes in the ovarian stroma of women with hyperthecosis of the ovaries.
Setting: Academic research environment.
Patient(s): Three women with ovarian hyperthecosis and eight with normal ov
ulatory cycles.
Intervention(s): Ovarian stromal tissues were obtained from women with hype
rthecosis and women with normal ovaries. Diagnosis of hyperthecosis was con
firmed by histologic examination of the ovaries. Steroid levels were measur
ed in the ovarian vein serum of one patient with hyperthecosis,
Main Outcome Measure(s): Tissues were frozen immediately in liquid nitrogen
and kept frozen until RNA was extracted. Total RNA was examined by Norther
n blot analysis using P-32-labeled complementary DNA (cDNA) probes encoding
human P450(scc) and P450(17 alpha) enzymes.
Result(s): P450(scc) and P450(17 alpha) messenger RNAs (mRNAs) were detecte
d in the normal ovarian stroma and stromal hyperthecosis. Compared with nor
mal ovarian stroma. P450(scc) mRNA was increased twofold and P450(17 alpha)
mRNA was increased threefold in stromal hyperthecosis.
Conclusion(s): [1] Ovarian stroma is probably the site of androgen producti
on in ovarian hyperthecosis. [2] Increased stromal androgen synthesis in hy
perthecosis could be due to increased expression of the enzymes P450(scc) a
nd P450(17 alpha) in the ovarian stroma, [3] Markedly increased concentrati
ons of 17 alpha-hydroxyprogesterone in the ovarian vein serum indicate poss
ible dysregulation of P450(17 alpha) in ovarian hyperthecosis. (Fertil Ster
il(R) 1999,71:328-33. (C) 1999 by American Society for Reproductive Medicin
e.)